Rankings
▼
Calendar
TGTX Q1 2021 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$793,000
+1986.8% YoY
Gross Profit
$654,000
82.5% margin
Operating Income
-$89M
-11248.7% margin
Net Income
-$91M
-11428.5% margin
EPS (Diluted)
$-0.69
QoQ Revenue Growth
+1986.8%
Cash Flow
Operating Cash Flow
-$81M
Free Cash Flow
-$81M
Stock-Based Comp.
$17M
Balance Sheet
Total Assets
$549M
Total Liabilities
$103M
Stockholders' Equity
$445M
Cash & Equivalents
$472M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$793,000
$38,000
+1986.8%
Gross Profit
$654,000
$38,000
+1621.1%
Operating Income
-$89M
-$50M
-77.5%
Net Income
-$91M
-$51M
-77.3%
Revenue Segments
Product
$755,000
95%
License
$38,000
5%
← FY 2021
All Quarters
Q2 2021 →